Astellas To Develop Beta-Secretase Inhibitor For Alzheimer’s In Deal With CoMentis
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma will front $80 million, an additional $20 million equity investment and up to $660 million in development milestones for rights to CoMentis' beta-secretase inhibitor program for Alzheimer's disease
You may also be interested in...
Alzheimer's Partnerships: Sharing Risks, Chasing Potentially Huge Rewards
Even now, decades after the first scientifically informed hypotheses about what causes Alzheimer's disease (AD), no consensus and thus no clear path towards treatment exists. Offsetting the uncertainty is the knowledge that a truly effective treatment would be a smashing success - potentially generating double-digit billions in annual global revenues
Alzheimer's Partnerships: Sharing Risks, Chasing Potentially Huge Rewards
Even now, decades after the first scientifically informed hypotheses about what causes Alzheimer's disease (AD), no consensus and thus no clear path towards treatment exists. Offsetting the uncertainty is the knowledge that a truly effective treatment would be a smashing success - potentially generating double-digit billions in annual global revenues
Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline
TOKYO - An Astellas Pharma senior executive said during a Feb. 2 earnings call the company is aiming to make its bid for CV Therapeutics a friendly proposal rather than a hostile takeover